Breaking News

Fujifilm CDI to Open iPS Cell Manufacturing Facility

$20 million cGMP facility will be located in Wisconsin and plans to open in 2020

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifim Cellular Dynamics, Inc. (FCDI), a U.S. subsidiary of Fujifilm Corporation, is investing about $21 million to open a new cGMP-compliant production facility with the goal of industrializing iPS cell manufacturing for regenerative medicine therapies. The Madison, WI facility will support FCDI’s internal cell therapeutics pipeline and will also serve as a contract development and manufacturing organization (CDMO) for iPS cell products.   Regenerative medicine is a highly advanced treatment...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters